Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results

Olema Pharmaceuticals (OLMA) has provided an announcement.

Olema Pharmaceuticals has shared promising interim results from a Phase 1b/2 trial combining palazestrant with ribociclib to treat ER+/HER2- metastatic breast cancer, which showed a high clinical benefit rate and good tolerance levels among patients. The study revealed that the combination therapy did not increase toxicity and maintained a favorable safety profile. These findings support further clinical development of the drug duo as a potential first-line treatment, which will be presented at the ESMO Breast Cancer Annual Congress.

For detailed information about OLMA stock, go to TipRanks’ Stock Analysis page.